A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

Phase 1/2 Recruiting 139 enrolled LaNova Medicines Limited

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is to assess the safety and tolerability, obtain Maximum Tolerated Dose (MTD) and/or the recommended phase 2 dose (RP2D) of LM-101 as a single agent or in combination in patients with advanced malignant tumors

Timeline

Start: 2023-01-11
Primary completion: 2027-01-11
Completion: 2028-01-11

Publications

Cai J, Zhao B, Ji D, Zhou F, Bai S, Fang X, Nie M, Bai B, Zhang Y, Li J, Li H, Li Y, Fei D, Qin X, Qin C, Zhao S, Xia Y, Cai Q. LM-101, an Anti-SIRPalpha Antibody, in Patients with Relapsed/Refractory Lymphoma and Advanced Head and Neck Cancer: An Open-Label, Multicenter, Phase I Trial. Clin Cancer Res. 2026 Jun 15;32(12):2391-2402. doi: 10.1158/1078-0432.CCR-25-2357.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LM-101	Unknown	3 mg/kg	Intravenous
Subject	LM-101	Unknown	10 mg/kg	Intravenous
Subject	LM-101	Unknown	20 mg/kg	Intravenous
Subject	LM-101	Unknown	30 mg/kg	Intravenous
Subject	LM-101	Unknown	40 mg/kg	Intravenous
Subject	Rituximab	Monoclonal antibody	—	Intravenous
Subject	Toripalimab	Monoclonal antibody	—	Intravenous

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

Summary

Timeline

Publications

Drugs

Indications